By Paul Kleutghen | Posted - Dec 22nd, 2017





Multiple Myeloma Word of the Day: APRIL

We will have to get used to APRIL as the new acronym to remember, and it is a doozy. APRIL stands for ‘anti proliferation inducing ligand’ and the first APRIL just entered Phase I/II clinical trials in the US. The APRIL compound, BION-1301, was developed by Aduro Biotech and has shown in pre-clinical studies that it is able to destroy malignant cells with minimal therapy resistance in disease models. BION-1301 is a humanized-APRIL-antibody and lab studies have shown that it fully blocks the APRIL-induced signaling cascade at a critical juncture. It is a little to close to Christmas to start explaining signaling cascades, especially since there are still Christmas presents to wrap. This early clinical study targets those patients whose disease progressed following a minimum of three previous systemic therapies with immunomodulatory drugs (IMiDs), proteasome inhibitors, chemotherapies or monoclonal antibodies [e.g., Darzalex]. The drug will be administered once every two weeks per 28-day cycle and the Phase I portion of the study will evaluate small groups of patients with different doses to evaluate drug safety and pharmacological parameters. The Phase II portion of the program will look at safety and efficacy of different dosing. First data about BION-1301 were presented at ASH 2017 earlier this month. For those who would like to learn more, click here: Aduro's APRIL Clinical Trial

Paul Kleutghen
About the Author

Paul Kleutghen - I am a patient diagnosed in 2014 with primary plasma cell leukemia (pPCL), a rare and aggressive variant of multiple myeloma and have been very fortunate to find treatment at the division of Cellular Therapy at the Duke University Cancer Institute. My wife, Vicki, and I have two adult children and a grandson who is the ‘light of my life’. Successful treatment has allowed Vicki and I to do what we love best : traveling the world, albeit it with some extra precautions to keep infections away. My career in the pharmaceutical industry has given me insights that I am currently putting to use as an advocate to lower drug pricing, especially prices for anti-cancer drugs and, very specifically, CAR-T therapies, with recent contributions posted by Health affairs, the Institute for Clinical and Economic Review and the Centers for Medicare and Medicaid Services.


Add a Comment



Thanks to our Myeloma Crowd Community sponsors:

.                         .       .